Authors:
Shepherd, FA
Fossella, FV
Lynch, T
Armand, JP
Rigas, JR
Kris, MG
Citation: Fa. Shepherd et al., Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials, SEMIN ONCOL, 28(1), 2001, pp. 4-9
Authors:
Fossella, FV
DeVore, R
Kerr, RN
Crawford, J
Natale, RR
Dunphy, F
Kalman, L
Miller, V
Lee, JS
Moore, M
Gandara, D
Karp, D
Vokes, E
Kris, M
Kim, Y
Gamza, F
Hammershaimb, L
Citation: Fv. Fossella et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated withplatinum-containing chemotherapy regimens, J CL ONCOL, 18(12), 2000, pp. 2354-2362
Authors:
Komaki, R
Roth, JA
Walsh, GL
Putnam, JB
Vaporciyan, A
Lee, JS
Fossella, FV
Chasen, M
Delclos, ME
Cox, JD
Citation: R. Komaki et al., Outcome predictors for 143 patients with superior sulcus tumors treated bymultidisciplinary approach at the University of Texas M. D. Anderson Cancer Center, INT J RAD O, 48(2), 2000, pp. 347-354
Authors:
Glisson, BS
Kurie, JM
Perez-Soler, R
Fox, NJ
Murphy, WK
Fossella, FV
Lee, JS
Ross, MB
Nyberg, DA
Pisters, KMW
Shin, DM
Hong, WK
Citation: Bs. Glisson et al., Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma, J CL ONCOL, 17(8), 1999, pp. 2309-2315
Authors:
Fossella, FV
Green, MR
Eckardt, JR
Wozniak, AJ
Socinski, MA
Murren, JR
Citation: Fv. Fossella et al., Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer - Discussion I, SEMIN ONCOL, 26(5), 1999, pp. 41-42
Citation: Fv. Fossella et J. Rigas, The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens, SEMIN ONCOL, 26(3), 1999, pp. 9-12